Biosplice Therapeutics

Biosplice Therapeutics, founded in 2008 and headquartered in San Diego, California, has raised approximately $778 million from investors including aMoon Fund, Eventide, SymBiosis II, Sands Capital, and Verition Fund Management. The company develops first-in-class small-molecule therapeutics by modulating alternative pre-mRNA splicing to treat degenerative and disease conditions such as osteoarthritis, oncology, and neurological disorders. A major $120 million venture funding round in 2021 supported advancement of its lead clinical programs and expansion of its therapeutic pipeline. With strong scientific backing and funding support, Biosplice is positioned to innovate in the next generation of biotech therapies.